The genetic landscape of programmed death ligand-1 (PD-L1) alterations in head and neck cancer.

ABSTRACT:

Objectives

Nivolumab has recently been shown in the phase III clinical trial CheckMate-141 to have superior survival rates compared to the current standard of care chemotherapy for recurrent or metastatic platinum-resistant head and neck squamous cell carcinoma (HNSCC). Nivolumab targets the immune inhibitory receptor programmed cell death 1 (PD-1). Programmed cell death ligand 1 (PD-L1) genomics have been poorly characterized in the context of HNSCC, including expression levels of PD-L1 in individual tumors as well as related up or down-regulated genes that might function as co-targets.

Study design

Data mining of The Cancer Genome Atlas (TCGA).

Methods

530 patients with HNSCC were pulled from the TCGA using cBioPortal. Primary tumor site data was available in 279 of

SUBMITTER: Heineman TE 

PROVIDER: S-EPMC5527359 | biostudies-literature | 2017 Jun

REPOSITORIES: biostudies-literature